glp-1 lawsuit news Ozempic for Blindness, Stomach Paralysis and Injury Claims Novo Nordisk A/S (NVO) Securities
Description
doi: 10.1016/j.neurobiolaging.2004.05.010 [DOI] [PubMed] [Google Scholar] 79
Lancet 389 , 139914097 (2017)
Even with these side effects, doctors often see the benefits of GLP-1s outweighing the risks
Despite rapid advancements in GLP-1/GIP dual-receptor agonist research, several areas warrant further investigation
3163 which focuses on NAION vision loss allegedly linked to GLP-1s MDL No
Qualifying criteria include BMI greater than 27 with prediabetes or established cardiovascular disease, or BMI over 30 with uncontrolled hypertension, advanced kidney disease, or heart failure
